VSVirginia Hernandez Santiago

Virginia Hernandez Santiago

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Virginia Hernandez Santiago has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Corticosteroids and antiviral treatment for Bell's palsy (idiopathic facial paralysis)

    by Peter Konstantin Kurotschka, Fergus Daly, Ildiko Gagyor, Maria Bauer, Franz E Babl, Virginia Hernandez Santiago, Maria Chiara Bassi, Dhruvashree Somasundara, Simon W Lowe, Frank Sullivan

    Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primary objective To evaluate the benefits and harms of corticosteroids, antiviral agents, and their combination, when given at onset for Bell’s palsy. Secondary objective To explore whether equity‐related factors, particularly age, influence the benefits or harms of those treatments.

  • Open Access

    Interventions for improving antibiotic prescribing in the community: systematic review and meta-analysis

    by Rebecca A J Andrews, Virginia Hernandez Santiago, Bruce Guthrie, Charis A Marwick

    Background: Antibiotic resistance is a public health priority and antibiotic use in humans is a major contributing factor to its development. Interventions to improve antibiotic prescribing in the community, where most antibiotics are prescribed, are widely implemented with varying effect. The aim was to systematically review and meta-analyse evidence on effectiveness of different types of antibiotic prescribing interventions in the community. Methods and Findings: Medline, Embase, and the Cochrane Central Register of Controlled Trials, were searched from database inception to 16 August 2021 to identify randomised controlled trials comparing antibiotic stewardship interventions versus usual care in community settings. Two reviewers screened studies, extracted data, and assessed risk of bias. Studies were grouped according to type of intervention. Meta-analyses employed random effects models. The outcome for meta-analyses was change in total antibiotic prescribing rates attributable to the intervention, compared to usual care, calculated as percentage differences. Other measures of change in antibiotic prescribing were included in narrative description. Of 26,130 studies screened, 74 were included, with 53 comparisons from 45 studies meta- analysed. 50% of included studies had high risk of bias. Single interventions with statistically significant reductions in total antibiotic prescribing were point of care tests for antigen detection (−28.0% reduction, 95%CI−38.2 to−17.8); educational materials (−17.0%, −31.0 to - 3.0); printed decision-support systems (−10.8%,−15.7 to -6.0), educational workshops (− 8.7%,−12.8 to -4.7), and; educational outreach (−6.0%,−10.6 to−1.4). Multifaceted interventions were not more effective than single interventions (education + audit and feedback –9.9%, −12.8 to -7.0; other multifaceted -9.4%, −17.2 to −1.6). Effect sizes in sensitivity analyses excluding trials at high risk of bias were similar or larger. Conclusions: Community antibiotic stewardship interventions were effective but with considerable variation in effect size. The most effective trial interventions may be more difficult to implement in practice, a key challenge for antibiotic stewardship. Systematic review registration PROSPERO CRD42014010160

  • Open Access

    Disrupted Candidacy: A Longitudinal Examination of the Constrained Healthcare‐Access Journeys of National Health Service Workers in Scotland Seeking Supports for Long COVID Illness

    by Nicholas Norman Adams, Emma MacIver, Flora Douglas, Catriona Kennedy, Diane Skåtun, Virginia Hernandez Santiago, Nicola Torrance, Aileen Grant

    Introduction: Evidence examines how persons experiencing Long COVID (LC) struggle to secure healthcare for symptoms. However, few studies examine healthcare workers experiencing LC, nor the complex and multiple difficulties faced when seeking and receiving healthcare.Methods: This study is based on two phases of longitudinally conducted qualitative interviews, 6 months apart, with National Health Service (NHS) workers experiencing LC, from different occupational roles at NHS locales in Scotland (first interviews, n = 50; second interviews, n = 44).Results: Multiple factors restricted healthcare access, including worries about pressuring the NHS and concerns over LC being legitimised. When healthcare was sought, workers struggled to secure support, referrals and treatment. The following reasons were included: (1) context: the restrictive pandemic healthcare context; (2) illness climate: low GP knowledge surrounding LC and how this could be treated, trends for ascribing symptoms to other causes and reluctance to diagnose LC; (3) sense‐making of LC: healthcare availability linked to occupational role identity. To visualise and examine healthcare barriers, candidacy theory is applied, drawing inferences between healthcare context, illness climate, sense‐making and identities.Conclusion: NHS workers' complex journeys represent Disrupted Candidacy, intersecting challenges across candidacy domains, restricting the seeking and receiving of LC healthcare. Findings provide insights into why NHS workers resisted and withdrew from healthcare‐seeking, and the barriers they faced when attempting to secure LC support. This study presents a pathway for future LC illness research to use a modified candidacy theory framework.Patient and Public Contribution: This research focuses on amplifying and learning from lived experiences, and the voices of NHS workers in Scotland experiencing LC. Interviews represent primary data for this study; thus, participants and their healthcare journeys are centred in this research and all aspects of production, reporting and output. Explicit discussions of stakeholder group involvement are highlighted in the methods section.


  • Intranasal steroid use and COVID-19 mortality among patients with asthma and COPD

    by Virginia Hernandez Santiago, Adeniyi Francis Fagbamigbe, Frank M Sullivan, Utkarsh Agrawal, Daniel Morales, Colin McCowan, Brian Lipworth


  • Open Access

    E. coli bacteraemia and antimicrobial resistance following antimicrobial prescribing for urinary tract infection in the community

    by Colin McCowan, Andisheh Bakhshi, Alex McConnachie, William Malcolm, Sarah Je Barry, Virginia Hernandez Santiago, Alistair Leanord

    Background: Urinary tract infections are one of the most common infections in primary and secondary care, with the majority of antimicrobial therapy initiated empirically before culture results are available. In some cases, however, over 40% of the bacteria that cause UTIs are resistant to some of the antimicrobials used, yet we do not know how the patient outcome is affected in terms of relapse, treatment failure, progression to more serious illness (bacteraemia) requiring hospitalization, and ultimately death. This study analyzed the current patterns of antimicrobial use for UTI in the community in Scotland, and factors for poor outcomes.Objectives: To explore antimicrobial use for UTI in the community in Scotland, and the relationship with patient characteristics and antimicrobial resistance inE. colibloodstream infections and subsequent mortality.Methods: We included all adult patients in Scotland with a positive blood culture withE. coligrowth, receiving at least one UTI-related antimicrobial (amoxicillin, amoxicillin/clavulanic acid, ciprofloxacin, trimethoprim, and nitrofurantoin) between 1st January 2009 and 31st December 2012. Univariate and multivariate logistic regression analysis was performed to understand the impact of age, gender, socioeconomic status, previous community antimicrobial exposure (including long-term use), prior treatment failure, and multi-morbidity, on the occurrence ofE. colibacteraemia, trimethoprim and nitrofurantoin resistance, and mortality.Results: There were 1,093,227 patients aged 16 to 100 years old identified as receiving at least one prescription for the 5 UTI-related antimicrobials during the study period. Antimicrobial use was particularly prevalent in the female elderly population, and 10% study population was on long-term antimicrobials. The greatest predictor for trimethoprim resistance inE. colibacteraemia was increasing age (OR 7.18, 95% CI 5.70 to 9.04 for the 65 years old and over group), followed by multi-morbidity (OR 5.42, 95% CI 4.82 to 6.09 for Charlson Index 3+). Prior antimicrobial use, along with prior treatment failure, male gender, and higher deprivation were also associated with a greater likelihood of a resistantE. colibacteraemia. Mortality was significantly associated with both having anE. colibloodstream infection, and those with resistant growth.Conclusion: Increasing age, increasing co-morbidity, lower socioeconomic status, and prior community antibiotic exposure were significantly associated with a resistantE. colibacteraemia, which leads to increased mortality.


  • Open Access

    Point-of-care tests for urinary tract infections: protocol for a systematic review and meta-analysis of diagnostic test accuracy

    by David Fraile Navarro, Frank Sullivan, Amaya Azcoaga-Lorenzo, Virginia Hernandez Santiago

    Introduction Urinary tract infections (UTIs) are the second most common type of infection worldwide, accounting for a large number of primary care consultations and antibiotic prescribing. Current diagnosis is based on an empirical approach, relying on symptoms and occasional use of urine dipsticks. The diagnostic reference standard is still urine culture, although it is not routinely recommended for uncomplicated UTIs in the community, due to time to diagnosis (48 hours). Faster point-of-care tests have been developed, but their diagnostic accuracy has not been compared. Our objective is to systematically review and meta-analyse the diagnostic accuracy of currently available point-of-care tests for UTIs. Methods and analysis Studies evaluating the diagnostic accuracy of point-of-care tests for UTIs will be included. PubMed, Web of Science, Embase and Cochrane Database of Systematic Reviews were searched from inception to 1 June 2019. Data extraction and risk-of-bias assessment will be assessed using the Quality Assessment of Diagnostic Accuracy Studies tool. Meta-analysis will be performed depending on data availability and heterogeneity. Ethics and dissemination This is a systematic review protocol and therefore formal ethical approval is not required, as no primary, identifiable, personal data will be collected. Patients or the public were not involved in the design of our research. However, the findings from this review will be shared with key stakeholders, including patient groups, clinicians and guideline developers, and will also be presented and national and international conferences. PROSPERO registration number CRD42018112019.


  • Open Access

    Changes in resistance among coliform bacteraemia associated with a primary care antimicrobial stewardship intervention: A population-based interrupted time series study

    by Virginia Hernandez-Santiago, Peter G Davey, Dilip Nathwani, Charis A Marwick, Bruce Guthrie

    Primary care antimicrobial stewardship interventions can improve antimicrobial prescribing, but there is less evidence that they reduce rates of resistant infection. This study examined changes in broad-spectrum antimicrobial prescribing in the community and resistance in people admitted to hospital with community-associated coliform bacteraemia associated with a primary care stewardship intervention. Segmented regression analysis of data on all patients registered with a general practitioner in the National Health Service (NHS) Tayside region in the east of Scotland, UK, from 1 January 2005 to 31 December 2015 was performed, examining associations between a primary care antimicrobial stewardship intervention in 2009 and primary care prescribing of fluoroquinolones, cephalosporins, and co-amoxiclav and resistance to the same three antimicrobials/classes among community-associated coliform bacteraemia. Prescribing outcomes were the rate per 1,000 population prescribed each antimicrobial/class per quarter. Resistance outcomes were proportion of community-associated (first 2 days of hospital admission) coliform (Escherichia coli, Proteus spp., or Klebsiella spp.) bacteraemia among adult (18+ years) patients resistant to each antimicrobial/class. 11.4% of 3,442,205 oral antimicrobial prescriptions dispensed in primary care over the study period were for targeted antimicrobials. There were large, statistically significant reductions in prescribing at 1 year postintervention that were larger by 3 years postintervention when the relative reduction was −68.8% (95% CI −76.3 to −62.1) and the absolute reduction −6.3 (−7.6 to −5.2) people exposed per 1,000 population per quarter for fluoroquinolones; relative −74.0% (−80.3 to −67.9) and absolute reduction −6.1 (−7.2 to −5.2) for cephalosporins; and relative −62.3% (−66.9 to −58.1) and absolute reduction −6.8 (−7.7 to −6.0) for co-amoxiclav, all compared to their prior trends. There were 2,143 eligible bacteraemia episodes involving 2,004 patients over the study period (mean age 73.7 [SD 14.8] years; 51.4% women). There was no increase in community-associated coliform bacteraemia admissions associated with reduced community broad-spectrum antimicrobial use. Resistance to targeted antimicrobials reduced by 3.5 years postintervention compared to prior trends, but this was not statistically significant for co-amoxiclav. Relative and absolute changes were −34.7% (95% CI −52.3 to −10.6) and −63.5 (−131.8 to −12.8) resistant bacteraemia per 1,000 bacteraemia per quarter for fluoroquinolones; −48.3% (−62.7 to −32.3) and −153.1 (−255.7 to −77.0) for cephalosporins; and −17.8% (−47.1 to 20.8) and −63.6 (−206.4 to 42.4) for co-amoxiclav, respectively. Overall, there was reversal of a previously rising rate of fluoroquinolone resistance and flattening of previously rising rates of cephalosporin and co-amoxiclav resistance. The limitations of this study include that associations are not definitive evidence of causation and that potential effects of underlying secular trends in the postintervention period and/or of other interventions occurring simultaneously cannot be definitively excluded. In this population-based study in Scotland, compared to prior trends, there were very large reductions in community broad-spectrum antimicrobial use associated with the stewardship intervention. In contrast, changes in resistance among coliform bacteraemia were more modest. Prevention of resistance through judicious use of new antimicrobials may be more effective than trying to reverse resistance that has become established.


  • Open Access

    Exploring the training and scope of practice of GPs in England, Germany and Spain

    by Ketevan Glonti, Verena Struckmann, Alvaro Alconada, Luisa M. Pettigrew, Virginia Hernandez-Santiago, Sergio Minue, Isabelle Risso-Gill, Martin McKee, Helena Legido-Quigley


  • Open Access

    Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients

    by Jesús López-Alcalde, Ricardo Rodriguez-Barrientos, Jesús Redondo-Sánchez, Javier Muñoz-Gutiérrez, José María Molero García, Carmen Rodríguez-Fernández, Julio Heras-Mosteiro, Jaime Marin-Cañada, Jose Casanova-Colominas, Amaya Azcoaga-Lorenzo, et al.

    Background Community‐acquired pneumonia (CAP) is a lung infection that can be acquired during day‐to‐day activities in the community (not while receiving care in a hospital). Community‐acquired pneumonia poses a significant public health burden in terms of mortality, morbidity, and costs. Shorter antibiotic courses for CAP may limit treatment costs and adverse effects, but the optimal duration of antibiotic treatment is uncertain. Objectives To evaluate the efficacy and safety of short‐course versus longer‐course treatment with the same antibiotic at the same daily dosage for CAP in non‐hospitalised adolescents and adults (outpatients). We planned to investigate non‐inferiority of short‐course versus longer‐term course treatment for efficacy outcomes, and superiority of short‐course treatment for safety outcomes. Search methods We searched CENTRAL, which contains the Cochrane Acute Respiratory Infections Group Specialised Register, MEDLINE, Embase, five other databases, and three trials registers on 28 September 2017 together with conference proceedings, reference checking, and contact with experts and pharmaceutical companies. Selection criteria Randomised controlled trials (RCTs) comparing short‐ and long‐courses of the same antibiotic for CAP in adolescent and adult outpatients. Data collection and analysis We planned to use standard Cochrane methods. Main results Our searches identified 5260 records. We did not identify any RCTs that compared short‐ and longer‐courses of the same antibiotic for the treatment of adolescents and adult outpatients with CAP. We excluded two RCTs that compared short courses (five compared to seven days) of the same antibiotic at the same daily dose because they evaluated antibiotics (gemifloxacin and telithromycin) not commonly used in practice for the treatment of CAP. In particular, gemifloxacin is no longer approved for the treatment of mild‐to‐moderate CAP due to its questionable risk‐benefit balance, and reported adverse effects. Moreover, the safety profile of telithromycin is also cause for concern. We found one ongoing study that we will assess for inclusion in future updates of the review. Authors' conclusions We found no eligible RCTs that studied a short‐course of antibiotic compared to a longer‐course (with the same antibiotic at the same daily dosage) for CAP in adolescent and adult outpatients. The effects of antibiotic therapy duration for CAP in adolescent and adult outpatients remains unclear.


  • Has primary care antimicrobial use really been increasing? Comparison of changes in different prescribing measures for a complete geographic population 1995–2014

    by Mark D J Neilly, Bruce Guthrie, Virginia Hernandez Santiago, Thenmalar Vadiveloo, Peter T Donnan, Charis A Marwick

    To elucidate how population trends in total antimicrobials dispensed in the community translate into individual exposure. Retrospective, population-based observational study of all antimicrobial prescribing in a Scottish region in financial years 1995, 2000 and 2005–14. Analysis of temporal changes in all antimicrobials and specific antimicrobials measured in: WHO DDD per 1000 population; prescriptions per 1000 population; proportion of population with ≥1 prescription; mean number of prescriptions per person receiving any; mean DDD per prescription. Antimicrobial DDD increased between 1995 and 2014, from 5651 to 6987 per 1000 population [difference 1336 (95% CI 1309–1363)]. Prescriptions per 1000 fell (from 821 to 667, difference –154, –151 to –157), as did the proportion prescribed any antimicrobial [from 39.3% to 30.8% (–8.5, –8.4 to –8.6)]. Rising mean DDD per prescription, from 6.88 in 1995 to 10.47 in 2014 (3.59, 3.55–3.63), drove rising total DDD. In the under-5s, every measure fell over time (68.2% fall in DDD per 1000; 60.7% fall in prescriptions per 1000). Among 5–64 year olds, prescriptions per 1000 were lowest in 2014 but among older people, despite a reduction since 2010, the 2014 rate was still higher than in 2000. Trends in individual antimicrobials provide some explanation for overall trends. Rising antimicrobial volumes up to 2011 were mainly due to rising DDD per prescription. Trends in dispensed drug volumes do not readily translate into information on individual exposure, which is more relevant for adverse consequences including emergence of resistance.